Trial Profile
An open-label 52-week safety study of bicifadine SR [sustained release] in adult outpatients with chronic peripheral neuropathic pain associated with diabetic peripheral neuropathy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2012
Price :
$35
*
At a glance
- Drugs Bicifadine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors XTL Biopharmaceuticals
- 01 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Feb 2008 New trial record.